Remedy Entertainment Oyj Statistics

Total Valuation

HEL:REMEDY has a market cap or net worth of EUR 241.58 million. The enterprise value is 229.32 million.

Market Cap	241.58M
Enterprise Value	229.32M

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

HEL:REMEDY has 13.59 million shares outstanding. The number of shares has increased by 0.61% in one year.

Current Share Class	13.59M
Shares Outstanding	13.59M
Shares Change (YoY)	+0.61%
Shares Change (QoQ)	+0.52%
Owned by Insiders (%)	45.04%
Owned by Institutions (%)	8.34%
Float	5.46M

Valuation Ratios

PE Ratio	n/a
Forward PE	31.19
PS Ratio	4.54
PB Ratio	3.46
P/TBV Ratio	4.28
P/FCF Ratio	21.29
P/OCF Ratio	102.71
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 42.47, with an EV/FCF ratio of 20.21.

EV / Earnings	-226.15
EV / Sales	4.31
EV / EBITDA	42.47
EV / EBIT	n/a
EV / FCF	20.21

Financial Position

The company has a current ratio of 3.33, with a Debt / Equity ratio of 0.23.

Current Ratio	3.33
Quick Ratio	3.33
Debt / Equity	0.23
Debt / EBITDA	2.91
Debt / FCF	1.38
Interest Coverage	-1.16

Financial Efficiency

Return on equity (ROE) is -1.47% and return on invested capital (ROIC) is -0.72%.

Return on Equity (ROE)	-1.47%
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	-0.72%
Return on Capital Employed (ROCE)	-1.07%
Revenue Per Employee	142,799
Profits Per Employee	-2,718
Employee Count	367
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -3.34% in the last 52 weeks. The beta is 0.79, so HEL:REMEDY's price volatility has been lower than the market average.

Beta (5Y)	0.79
52-Week Price Change	-3.34%
50-Day Moving Average	14.48
200-Day Moving Average	15.03
Relative Strength Index (RSI)	78.93
Average Volume (20 Days)	8,156

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HEL:REMEDY had revenue of EUR 53.26 million and -1.01 million in losses. Loss per share was -0.07.

Revenue	53.26M
Gross Profit	37.95M
Operating Income	-903,000
Pretax Income	-756,000
Net Income	-1.01M
EBITDA	4.02M
EBIT	-903,000
Loss Per Share	-0.07

Full Income Statement

Balance Sheet

The company has 27.97 million in cash and 15.71 million in debt, giving a net cash position of 12.26 million or 0.90 per share.

Cash & Cash Equivalents	27.97M
Total Debt	15.71M
Net Cash	12.26M
Net Cash Per Share	0.90
Equity (Book Value)	69.79M
Book Value Per Share	5.14
Working Capital	30.41M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.35 million and capital expenditures 9.00 million, giving a free cash flow of 11.35 million.

Operating Cash Flow	2.35M
Capital Expenditures	9.00M
Free Cash Flow	11.35M
FCF Per Share	0.84

Full Cash Flow Statement

Margins

Gross margin is 71.25%, with operating and profit margins of -1.70% and -1.90%.

Gross Margin	71.25%
Operating Margin	-1.70%
Pretax Margin	-1.42%
Profit Margin	-1.90%
EBITDA Margin	7.55%
EBIT Margin	-1.70%
FCF Margin	21.30%

Dividends & Yields

HEL:REMEDY does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.61%
Shareholder Yield	-0.61%
Earnings Yield	-0.42%
FCF Yield	4.70%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

HEL:REMEDY has an Altman Z-Score of 5.77.

Altman Z-Score	5.77
Piotroski F-Score	n/a